» Articles » PMID: 21471242

Enzyme Digests Eliminate Nonfunctional Env from HIV-1 Particle Surfaces, Leaving Native Env Trimers Intact and Viral Infectivity Unaffected

Overview
Journal J Virol
Date 2011 Apr 8
PMID 21471242
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

HIV-1 viruses and virus-like particles (VLPs) bear nonnative "junk" forms of envelope (Env) glycoprotein that may undermine the development of antibody responses against functional gp120/gp41 trimers, thereby blunting the ability of particles to elicit neutralizing antibodies. Here, we sought to better understand the nature of junk Env with a view to devising strategies for its removal. Initial studies revealed that native trimers were surprisingly stable in the face of harsh conditions, suggesting that junk Env is unlikely to arise by trimer dissociation or gp120 shedding. Furthermore, the limited gp120 shedding that occurs immediately after synthesis of primary HIV-1 isolate Envs is not caused by aberrant cleavage at the tandem gp120/gp41 cleavage sites, which were found to cleave in a codependent manner. A major VLP contaminant was found to consist of an early, monomeric form of gp160 that is glycosylated in the endoplasmic reticulum (gp160ER) and then bypasses protein maturation and traffics directly into particles. gp160ER was found to bind two copies of monoclonal antibody (MAb) 2G12, consistent with its exclusively high-mannose glycan profile. These findings prompted us to evaluate enzyme digests as a way to remove aberrant Env. Remarkably, sequential glycosidase-protease digests led to a complete or near-complete removal of junk Env from many viral strains, leaving trimers and viral infectivity largely intact. "Trimer VLPs" may be useful neutralizing antibody immunogens.

Citing Articles

Current methods for detecting and assessing HIV-1 antibody resistance.

Odidika S, Pirkl M, Lengauer T, Schommers P Front Immunol. 2025; 15():1443377.

PMID: 39835119 PMC: 11743526. DOI: 10.3389/fimmu.2024.1443377.


Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation.

Ding H, Nguyen H, Li W, Deshpande A, Zhang S, Jiang F J Virol. 2024; 98(12):e0172024.

PMID: 39508605 PMC: 11650979. DOI: 10.1128/jvi.01720-24.


Impact of glycan depletion, glycan debranching and increased glycan charge on HIV-1 neutralization sensitivity and immunogenicity.

DAddabbo A, Tong T, Crooks E, Osawa K, Xu J, Thomas A Glycobiology. 2024; 34(11).

PMID: 39115361 PMC: 11442005. DOI: 10.1093/glycob/cwae063.


Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.

Rao P, Lambert G, Upadhyay C J Virol. 2023; 97(9):e0071023.

PMID: 37681958 PMC: 10537810. DOI: 10.1128/jvi.00710-23.


Impact of stabilizing mutations on the antigenic profile and glycosylation of membrane-expressed HIV-1 envelope glycoprotein.

Tong T, DAddabbo A, Xu J, Chawla H, Nguyen A, Ochoa P PLoS Pathog. 2023; 19(8):e1011452.

PMID: 37549185 PMC: 10434953. DOI: 10.1371/journal.ppat.1011452.


References
1.
Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N . Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996; 70(2):1100-8. PMC: 189917. DOI: 10.1128/JVI.70.2.1100-1108.1996. View

2.
Gray E, Moore P, Pantophlet R, Morris L . N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J Virol. 2007; 81(19):10769-76. PMC: 2045459. DOI: 10.1128/JVI.01106-07. View

3.
Kang Y, Andjelic S, Binley J, Crooks E, Franti M, Iyer S . Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine. 2009; 27(37):5120-32. PMC: 4340663. DOI: 10.1016/j.vaccine.2009.06.037. View

4.
Wang X, Zhang L, Chi Y, Hoellwarth J, Zhou S, Wen X . The nature and combination of subunits used in epitope-based Schistosoma japonicum vaccine formulations affect their efficacy. Parasit Vectors. 2010; 3:109. PMC: 3136145. DOI: 10.1186/1756-3305-3-109. View

5.
Larke N, Im E, Wagner R, Williamson C, Williamson A, McMichael A . Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur J Immunol. 2007; 37(2):566-77. DOI: 10.1002/eji.200636711. View